Evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer survivors: study protocol for a randomized controlled trial by Jefford, Michael et al.
 DRO  
Deakin Research Online, 
Deakin University’s Research Repository  Deakin University CRICOS Provider Code: 00113B 
Evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer 
survivors: study protocol for a randomized controlled trial 
Citation: 
Jefford, Michael, Aranda, Sanchia, Gough, Karla, Lotfi-Jam, Kerryann, Butow, Phyllis, 
Krishnasamy, Mei, Young, Jane, Phipps-Nelson, Jo, Russell, Lahiru, King, Dorothy and Schofield, 
Penelope 2013, Evaluating a nurse-led survivorship care package (SurvivorCare) for bowel cancer 
survivors: study protocol for a randomized controlled trial, Trials, vol. 14, pp. 1-9. 
DOI: 10.1186/1745-6215-14-260 
 
 
 
 
 
©2013, Jefford et al. 
Reproduced by Deakin University under the terms of the Creative Commons Attribution Licence 
 
 
 
 
 
Downloaded from DRO: 
http://hdl.handle.net/10536/DRO/DU:30128404  
TRIALS
Jefford et al. Trials 2013, 14:260
http://www.trialsjournal.com/content/14/1/260STUDY PROTOCOL Open AccessEvaluating a nurse-led survivorship care package
(SurvivorCare) for bowel cancer survivors: study
protocol for a randomized controlled trial
Michael Jefford1,2,3*, Sanchia Aranda1,2,3,4, Karla Gough1, Kerryann Lotfi-Jam1,5, Phyllis Butow6,7,
Mei Krishnasamy1,2,3,5, Jane Young6,8,9, Jo Phipps-Nelson1, Lahiru Russell1, Dorothy King1
and Penelope Schofield1,2,3,5Abstract
Background: Colorectal cancer (CRC) is the most common cancer affecting both men and women in Australia. The
illness and related treatments can cause distressing adverse effects, impact on emotional and psychological
well-being, and adversely affect social, occupational and relationship functioning for many years after the end of
treatment or, in fact, lifelong. Current models of follow-up fail to address the complex needs arising after treatment
completion. Strategies to better prepare and support survivors are urgently required. We previously developed a
nurse-led supportive care program (SurvivorCare) and tested it in a pilot study involving 10 CRC survivors. The
intervention was found to be highly acceptable, appropriate, relevant and useful.
Methods/design: This study is a multisite, randomised controlled trial, designed to assess the impact of the
addition of the SurvivorCare intervention to usual post-treatment care, for people with potentially cured CRC.
SurvivorCare comprises the provision of survivorship educational materials, a tailored survivorship care plan, an
individually tailored nurse-led, face-to-face end of treatment consultation and three subsequent telephone calls.
Eligible patients have completed treatment for potentially cured CRC. Other eligibility criteria include stage I to III
disease, age greater than 18 years and adequate understanding of English. All consenting patients complete
questionnaires at three time points over a six-month period (baseline, two and six months). Measures assess
psychological distress, unmet needs and quality of life.
Discussion: This supportive care package has the potential to significantly reduce individual suffering, whilst
reducing the burden of follow-up on acute cancer services through enhanced engagement with and utilisation of
general practitioners and community based services. If the intervention is successful in achieving the expected
health benefits, it could be disseminated readily. All training and supporting materials have been developed and
standardised. Furthermore, the intervention could easily be adapted to other cancer or chronic disease settings.
Trial registration: Australian New Zealand Clinical Trial Registry ACTRN12610000207011.
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In Australia, bowel cancer is the most common cancer
affecting both men and women [1]. Although it is the
second highest cause of death from cancer (after lung
cancer), many people are long-term survivors. Survivors
of bowel cancer represent the third largest group of long-
term cancer survivors in the Western world (after survi-
vors of breast and prostate cancer) with five-year survival
rates of approximately 55% [2]. It is expected that the
number of people affected by and surviving bowel cancer
will rise significantly over the next 10 years. Australian
data showed a 30% increase in the number of new or sur-
viving cases of colorectal cancer (CRC) in women and
33% for men between 2001 and 2011 [1].
CRC survivors are vulnerable to a number of distressing
long-term sequelae [3-8]. Forty percent of people thought
to be cured will ultimately develop recurrent disease [9].
In addition, survivors of CRC are at increased risk of de-
veloping a second cancer, either bowel cancer or another
primary cancer [9]. Survivors are susceptible to surgical
complications, such as bowel obstruction, abdominal wall
hernias and altered bowel function [4,5].
Rectal cancer survivors are at risk of faecal, bladder
and sexual dysfunction [5-8]. Bowel dysfunction may in-
clude faecal frequency and urgency, faecal leakage, and
the need to use pads. Surgery and radiation treatment for
rectal cancer may result in long-term and late conse-
quences, such as chronic diarrhoea, poor food absorption,
potential early menopause in some women, loss of fertility
in both men and women, damage to the vagina and im-
paired ability to achieve erections [6-9]. Chemotherapy
can result in persistent peripheral neuropathy resulting in
pain and loss of function, impacting upon activities of
daily life.
Given these serious side-effects, not surprisingly social,
occupational and relationship functioning commonly suffer
[9-13]. Many survivors do not return to full-time work, or
may have a delayed return to work [14]. This, in addition
to out of pocket expenses, can impose a significant finan-
cial burden [10,11]. Some survivors experience reduced so-
cial integration and changes in their intimate relationships.
Many suffer ongoing psychosocial distress, especially those
managing permanent colostomies [7,8,10]. Studies suggest
an increased rate of depression compared with matched
groups unaffected by cancer [12]. Schag and colleagues
found, even at five-year follow-up, that many colon cancer
survivors reported difficulties with physical functioning,
poor energy levels, difficulty undertaking recreational activ-
ities, ongoing concerns about recurrence, body image con-
cerns, problems with sexual interest and functioning, and
work problems [13]. Despite these significant challenges,
colorectal cancer survivors are underrepresented in sur-
vivorship research in general [15]. The current investigators
were unable to identify any published research describinginterventions to better support bowel cancer survivors fol-
lowing treatment completion.
The current project seeks to evaluate an innovative
nurse-led supportive care program (SurvivorCare). The
intervention was developed by experts and key stake-
holders in supportive care research after extensive quan-
titative and qualitative research with colorectal cancer
survivors (consumers) and health care professionals [16,17].
Consumer and health care professionals’ perspectives were
sought to determine the relevance of the proposed Sur-
vivorship Care Plan (SCP) elements [16]. Specifically, the
intervention is designed to: 1) be patient-centred by elic-
iting individual concerns and needs to direct personal
health care plans; 2) provide comprehensive post-treatment
care coordination by a specialist intervention nurse to ad-
dress the multifaceted supportive care post-treatment needs
of this patient group; 3) provide instruction in evidence-
based self-care and stress reduction strategies to better en-
able people to manage self-care requirements in the period
of cancer survivorship following treatment completion; 4)
provide tailored information to patients and their sig-
nificant others in order to maximise information relevance
to this specific survivorship period; 5) if not already im-
plemented, coordinate appropriate post-treatment care
referrals to community and multidisciplinary health profes-
sionals where relevant; and 6) provide a sustainable model
of nurse-led survivorship care centred on standardised end
of treatment processes and enhanced collaboration and
communication with primary care.
The complete SurvivorCare package (DVD, booklet,
Question Prompt List (QPL), Survivorship Care Plan
(SCP), end of treatment session and telephone follow-up)
was trialed with 10 participants to examine appropriate-
ness, acceptability and clinical feasibility in a pilot test
trial. SurvivorCare proved to be a well-received, compre-
hensive intervention by the participants and nurses [18].Study aim
This study seeks to examine the effectiveness of an in-
novative supportive care program (SurvivorCare) com-
prising survivorship educational materials, provision of
a tailored SCP, an individually tailored nurse-led end of
treatment consultation and telephone follow-up for people
with potentially cured colorectal cancer, aiming to reduce
psychological distress and unmet needs in the six months
following treatment completion.Study hypotheses
Primary endpoint
CRC survivors allocated to the SurvivorCare intervention
will report a significant relative benefit for psychological
distress compared to survivors in the control group from
baseline to Follow-up 1 (eight weeks after randomisation
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intervention session for the SurvivorCare group).
Secondary endpoints
Compared to patients in control groups, patients allo-
cated to SurvivorCare will report:
(i) Significant beneficial effect for unmet psychological
and informational needs, and quality of life from
Baseline to Follow-up 1;
(ii) Sustained improvement in psychosocial outcomes
over six months.
Methods
Design and setting
The study is being undertaken at 18 sites within
Australia. Peter MacCallum Cancer Centre is the coord-
inating site, with all participant data stored centrally. A
feasibility survey was conducted in January 2009. Sites
were selected based on their proximity to patients in
addition to the availability of at least one nurse to admin-
ister the SurvivorCare intervention. Ideally, the nurse
would be a specialist colorectal cancer nurse; however,
nurses with general oncology experience were also eligible.
Availability of site resources/space to conduct the study
was also considered.
Ethical approval was obtained individually by the Human
Research Ethics Committees of Victorian and Tasmanian
sites, and a central governance approval was obtained for
all sites in New South Wales.
Participants
To be eligible, participants need to: (1) have a confirmed
diagnosis of colon or rectal cancer; (2) have stage I to III
disease (that is, non-metastatic); (3) be treated with cura-
tive intent with surgery +/− radiation +/− chemotherapy;
(4) be over 18 years; and (5) be able to understand English.
Exclusion criteria are (1) demonstrated cognitive or psy-
chological difficulties as defined by the treatment team’s
assessment or documented within the patient’s medical
history; (2) too unwell to participate in the study as deter-
mined by the patient’s treatment team; (3) past history of
malignancy other than non-melanomatous skin cancer;
(4) enrolment in a conflicting supportive care trial that
might impact the study’s measured endpoints.
Recruitment process
Patient eligibility is confirmed with the treating clinician.
The study is further explained to patients by a trained
data manager and written consent is obtained. Patients are
approached zero to six months prior to the end of treat-
ment (preferably), or up to six months after the end of
treatment. Once the study coordinating centre receives
a patient randomisation request by fax or email from aparticipating site, the patient is randomised 1:1 to either
usual care or SurvivorCare (100 patients are expected in
each arm). The type of treatment and hospital site is en-
tered in an Access database, where the allocation is bal-
anced by site using a minimisation method. Figure 1
illustrates a schematic diagram of the study design.
Intervention group/SurvivorCare
The intervention consists of four main components: (1)
information package; (2) nurse-led face-to-face end of
treatment session; (3) SCP; and (4) telephone follow-up.
(1) Information package
The package includes a DVD (Just Take It Day to
Day) [19], a booklet (Life After Cancer) [20], and a
Question Prompt List (QPL). The QPL is a list of 70
questions covering common issues cancer survivors
encounter in the first year following treatment. Ten
main topics covering issues and concerns around
coping, physical consequences of completing
treatment, late and long-term effects of treatment,
impact on family and friends, recurrence, follow-up
planning, fertility, pregnancy and menopause,
sexuality, dealing with practical matters, such as
finances, returning to work and insurance, and need
for further information and support, are listed to
help the patient think about what they might like to
ask their nurse or doctor. The patient is asked to
view the material and complete the QPL prior to the
nurse-led face-to-face session.
(2) Nurse-led face-to-face session
A nurse-led end of treatment session will take place
in a standard timeframe after randomisation. Focus
group results and a review of the literature [17] and
expert input were used to design the end of
treatment session, which addresses current
concerns, seeks to attain a sense of closure on
treatment and aims to prepare people for the
survivorship phase and introduce telephone
follow-up. The session takes place in a private
hospital clinic room by a nurse trained to deliver the
intervention. Session time is 60 to 90 minutes.
Significant others are encouraged to also attend the
end of treatment consultation to maximise the
positive impact on patient outcomes [21,22].
Additional concerns not covered in the session are
covered in subsequent telephone follow-up sessions.
The session incorporates seven elements.
Normalising treatment completion concerns
The vast majority of patients feel a degree of uncertainty
for what lies ahead. Discussing treatment completion
and the future will be addressed for all patients in the
intervention arm.
Identification of eligible patients 
Inclusion: Stage I-III colon/rectal cancer, 
treated with curative intent, over 18 years, 
speaks English.
Exclusion: Psychological and cognitive 
difficulties, too unwell, previous 
malignancies, metastatic cancer at time of 
recruitment, enrolled in a conflicting trial.
Approach eligible patients 
(N=250)
Consent patient and register 
(N=200)
Baseline questionnaire
Measure: BSI-18, DT, CaSUN, 
EORT QLQ CR-  
demographics and medical records
Randomise patients
Patient refusals (collect 
reason for refusal)
Intervention arm (N=100)
Information provision at randomisation 
DVD, Booklet and Question prompt List
Usual Care arm(N=100)
Care provided according to treating 
centre/ practitioners’ usual practice. Key 
elements of the intervention will not be 
provided for the duration of the study.
Nurse-led end of treatment session
1-2 weeks after randomisation
Normalise end of treatment concerns
Tailored, evidence -based advice
Referrals to multidisciplinary team 
members as necessary
Discuss survivorship care plan and 
follow-up
Coaching
Referral to peer support program
Survivorship care plan sent to GP and 
cancer specialists
Nurse-led telephone follow-up calls
1, 3 and 7 weeks after randomisation
Normalise end of treatment concerns
Discuss previously identified needs
Screen for distress, unmet needs
Encourage adherence to self-care 
strategies
Promote shared care/ GP involvement
Follow up 1 questionnaire
8 weeks after randomisation for usual care or 
1st intervention session for SurvivorCare 
(N=90 per arm, 10% attrition from 
Baseline)
Measures: BSI-18, DT, CaSUN, EORTC QLQ 
CR-30 and CR
Follow up 2 questionnaire
6 months after randomisation for usual care or 
1st intervention session for SurvivorCare 
Measures: BSI-18, DT, CaSUN, EORTC QLQ 
CR-30 and CR
Figure 1 Schematic diagram of Survivor Care study design.
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At the beginning of the session, survivors score their
current level of distress using the Distress Thermometer
(DT) and indicate any queries or questions using the QPL.
Level of distress noted on the DT and problem areas iden-
tified through the QPL will be used to guide a discussion
of individual needs and prompt referral to other services.
The patient will be asked to identify their top three
concerns for focus during the session. Evidence-based
self-management strategies will be provided to deal with
side-effects. An intervention manual includes evidence-
based guidance regarding all 69 questions from the QPL;
together with additional information and resources (for
example, information and support services for people witha stoma or managing continence issues). All information,
processes and outcomes from the session are recorded in
an End of Treatment Session Checklist.Referral to multi-disciplinary and community referrals
Survivors may experience a range of unmet suppor-
tive care needs. Research shows that nurse co-ordinated
multi-disciplinary and community referrals result in
better symptom control for cancer patients [23]. Nurses
will offer (and organise where necessary) appropriate
multidisciplinary and community referrals for unmet
needs identified on the problem checklist from the DT
or QPL.
Table 1 Features of the intervention covered during the
post end of treatment sessions
Elements of the SurvivorCare
intervention
Covered
during initial
session
Covered during
follow-up
sessions
Discussion of the survivorship care
plan and introduction to follow-up
Yes
Coaching Yes
Referral to peer support programs Yes
Normalising of common end of
treatment concerns
Yes
Discuss current concerns and
advice
Yes Yes
Referral to multi-disciplinary and
community referrals
Yes Yes
Screen for distress Yes Yes
Encourage adherence to
self-care strategies
Yes Yes
Promote shared care/GP
involvement
Yes Yes
Jefford et al. Trials 2013, 14:260 Page 5 of 9
http://www.trialsjournal.com/content/14/1/260Recommendations regarding follow-up and discussion of
the survivorship care plan
The SCP includes details of the cancer diagnosis, treat-
ments, health promotional advice, supportive care and
psychosocial elements, as well as recommendations for
follow-up to detect cancer recurrence. The SCP will be
reviewed and the importance of follow-up to screen for
physical and supportive care issues will be emphasised.
Patients will be given a SCP during the end of treatment
session. Their general practitioner and oncology special-
ists will also be sent a copy.
Liaison with the patient’s GP
Patients will be encouraged to discuss aspects of their
survivorship care that might be best transitioned to their
GP. Discussion will also cover aspects of care being
managed by the patient’s GP and aspects of care for
management by the specialist. This will be documented
in the SCP. Patients will be advised that their GPs will
also receive the SCP and recommendations regarding
detection of cancer recurrence and screening for sur-
vivorship needs. The benefits of shared care with the GP
will be emphasised. Thus, the transition from intensive
hospital treatment to community-based GP maintenance,
mediated through nurse-led phone follow-up will be en-
couraged. Discussion will also include appropriate time
points for follow-up by medical specialists.
Coaching
Health promotional strategies, such as stopping smoking,
exercising and losing weight will be discussed where these
are identified as issues for the survivor or the health pro-
fessional. Intervention nurses will be trained to assess
patients’ readiness to make behavioural change and will
assist participants to establish behavioural change goals.
Coaching and rehearsal of self-care for side-effects and
stress-reduction strategies will be offered and reinforced
during telephone follow-up sessions.
Referral to peer support programs
All participants will be referred to peer support programs.
Cancer Councils operate a free, one-to-one telephone-
based peer support program called Cancer Connect. Vol-
unteers are CRC survivors who have received rigorous
training, including communication skills (asking open
questions, empathy, active listening) and encouraging
coping and adherence to self-care and health promo-
tional advice. Patients will also be advised of other
community-based resources, including cancer support
groups and the Cancer Council Helpline.
Nurse-led telephone follow-up
These sessions will take place one, three and seven weeks
after the first intervention session. The purpose of thesessions are to: a) support the patient during the post
treatment completion period to reduce feelings of isola-
tion or abandonment from the hospital team; (b) revisit
needs discussed during the end of treatment session and
explore in detail and respond to any concerns not ad-
dressed at that session; (c) screen for psychosocial distress
and additional unmet needs using the Distress Thermom-
eter, issues highlighted in the QPL and the Survivor Care
Plan; (d) encourage adherence to recommended self-care
strategies and planned health behaviour change goals, and
(e) emphasise the collaborative relationship between the
patient’s GP and hospital team, highlighting that the pa-
tient’s GP has been provided with relevant information to
enable effective shared care. Appointments will be made
for the three calls, at the end of treatment session. The pa-
tient’s shared care team will be notified of any new con-
cerns identified by the patient or nurse during telephone
follow-up, as well as significantly high levels of psycho-
social distress, and additional unmet needs. New patient
concerns will be followed up by the intervention nurse
at subsequent telephone follow-ups. Table 1 offers a sum-
mary of the elements covered by the intervention during
the initial and follow-up sessions.
Usual care/control group
Participants allocated to usual care will receive care ac-
cording to the treating centre/practitioner’s usual practice.
Key elements of the intervention will not be provided in
the control group (tailored, nurse-led, face-to-face and tele-
phone sessions, question prompt list, self-care resources,
SCP and GP correspondence). Participating health care
services will be asked not to incorporate similar elements
into usual care for the duration of the study. Participants
Table 2 Time points measuring patient reported
outcomes for the SurvivorCare study
Time point Questionnaire
Baseline: on the day of randomisation
(zero to two weeks before a potential
first intervention session)
Demographic variables, Medical
records, BSI-18, DT, CaSUN, EORTC
QLQ C-30 and CR-29.
Follow-up 1: eight weeks after
randomisation date for usual care
patient or after the first session
date for intervention patients
BSI-18, DT, CaSUN, EORTC QLQ C-
30 and CR-29 and Satisfaction
Measure with usual care checklist
Follow-up 2: six months after
randomisation date for usual care
patient or the first session date
for intervention patients
BSI-18, DT, CaSUN, EORTC QLQ
C30 and CR-29
BSI-18, Brief Symptom Inventory; CaSUN, Cancer Survivors’ Unmet Needs
Measure; DT, Distress Thermometer; EORTC QLQ C-30, European Organisation
for Research and Treatment of Cancer core questionnaire; EORTC QLQ CR-29,
the colorectal cancer module.
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they have received any components of the SurvivorCare
intervention, for example, information materials, SCP.
Intervention staff training
Intervention nurses with experience looking after people
with bowel cancer have been trained to provide the end
of treatment and telephone follow-up sessions at each
site. An expert in communication skills training and two
experts in nurse-led clinics and self-care education con-
ducted a full-day training program comprising: (a) an over-
view of the project, emphasising prevention of diffusion of
the intervention at the site; (b) explanation of how to use
the intervention manual; (c) training in eliciting and re-
sponding to emotional cues, including dealing with distress;
(d) instruction on exploring concerns and providing
evidence-based advice; (e) instruction in how to effectively
facilitate referral to multidisciplinary team members; (f) in-
struction on how to coach patients to use evidence-based
strategies; (g) role-play with simulated patients (actors) and
activity sessions to practice the intervention, including self-
appraisal and constructive feedback.
Data manager training
Data managers (DMs) with experience in participant re-
cruitment and coordinating research projects were trained
to identify eligible patients, liaise with hospital staff and
intervention nurses, approach patients, administer sur-
veys, manage participant databases, and report data back
to the project team. DMs were also trained on patient ran-
domisation techniques.
Study integrity and quality assurance
Efforts will be made to ensure that the intervention nurse
will not be involved in follow-up of patients receiving
usual care, to avoid contamination. At sites where only
one nurse is available to administer both the intervention
and usual care to patients, the intervention nurse will be
given specific training to ensure that patients in the con-
trol group will not be given additional post-treatment care
in addition to usual care.
A usual care checklist will be sent out with the first
follow-up questionnaire to all patients in the usual care
arm to determine whether patients have received ele-
ments of the intervention, such as the DVD, the booklet
or SCP.
An intervention manual summarising details of the in-
tervention was developed to train the nurses delivering
the intervention. Intervention procedures will strictly be
monitored for adherence to the manual. All intervention
sessions will be audio-taped. The first 10 sessions will be
reviewed to ensure adherence against a checklist derived
from the manual. After this, a random sample of 15% of
all sessions will continue to be reviewed. To ensure thatcompetency is maintained, regular feedback sessions will
be arranged.
Reasons for attrition will be recorded, and recruitment
and drop-out bias assessed.
Data collection procedure
Participants will be asked to complete a baseline question-
naire on the day of randomisation and two subsequent
follow-up questionnaires at eight weeks (Follow-up 1) and
six months (Follow-up 2) after the face-to-face session for
the intervention group or after randomisation for the
usual care group. Table 2 shows data to be collected.
Demographic information
Data to be collected include age, gender, marital status, age
of any children, postcode, occupation and education level.
Medical records
Data will include cancer type, stage, treatment, time
since diagnosis, treatment outcomes, recurrence, treat-
ment side-effects/toxicities, performance status, other
non-cancer morbidities, unscheduled/emergency appoint-
ments at treating centre and other identified centres,
admissions as an inpatient, addition to or changes in
medication prescriptions to manage toxicities and re-
ferrals to allied health services at the treating centre.
Psychological distress
The Brief Symptom Inventory 18 (BSI-18) was selected as
the primary outcome measure [24]. It comprises 18 items
answered on a 5-point scale to score global distress. Sub-
scales assess anxiety, depression and somatisation. It has
demonstrated reliability, validity, acceptability and respon-
siveness and has been used extensively in both cancer and
general populations. It has been recommended for use in
identifying psychological distress in a clinical setting [25].
The Distress Thermometer (DT) [26] is a reliable and valid
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which appears responsive to change [27].
Survivors unmet needs
Cancer Survivors’ Unmet Needs measure (CaSUN) [28] will
be used to assess survivors’ unmet needs. It includes 35 un-
met need items, 6 positive change items and an open-
ended question. The scale has good acceptability, internal
consistency and validity. A review of measures of survivors’
unmet needs suggests that the CaSUN performs as well, or
better, than any other measure [29].
Quality of life
The European Organisation for Research and Treatment
of Cancer core questionnaire (EORTC QLQ C-30) [30]
will be used together with the colorectal cancer module
(EORTC QLQ CR-29) [31] to measure quality of life. To-
gether, the scales include 59 items that assess quality of life
issues specific to this patient group. The measures are
widely used, with good test-retest reliability, validity, re-
sponsiveness and acceptability.
Sample size requirements
The primary outcome for this longitudinal randomised
controlled trial is psychological distress as assessed by the
BSI-18 Global Severity Index, an 18-item scale with a pos-
sible range of 72. The BSI-18 will be completed once at
baseline and twice post-intervention, but the main con-
trast of interest is the difference between arms at the first
post-intervention follow-up.
In this case, we based our sample size calculations on
80% power, a two-sided t-test with an alpha-level of 0.05,
a difference between groups of 3.6 points on the primary
outcome (or 5% of the instrument range) [32] and a stand-
ard deviation of 8.6 [24] (a standardised difference of
0.42). Given these specifications, the required sample size
is 180 patients (or 90 patients per arm). Assuming attri-
tion of up to 10%, 200 patients will need to be recruited
(or 100 patients per arm). Furthermore, assuming an 80%
recruitment rate, approximately 250 patients will need to
be approached to achieve a total sample of 200 patients.
Patients will be recruited over 24 months.
Statistical analysis
Analyses will be by intention-to-treat and performed in
SPSS Windows Version 21.0 (or higher) (Chicago, IL,
USA). Prior to formal analyses, descriptive statistics and
graphical displays will be used to identify missing and
out-of-range values, assess the distributional characteristics
of test scores and summarise study measure completion
rates and missing data points. Responses to the BSI-18,
DT, CaSUN, EORTC QLQ C-30 and CR-29 will be scored
according to algorithms in the users’ manuals for these
instruments.Descriptive statistics will be used to summarise base-
line demographic and clinical characteristics of patients
randomised to the intervention and usual care. Recruitment
bias and possible differential attrition will be assessed by
comparing basic demographic and clinical characteristics of
responders and non-responders, as well as drop-outs and
continuing participants, using t-tests (or Mann–Whitney
U) and chi-squared tests as appropriate.
Primary and secondary outcome analyses will be car-
ried out by fitting a linear mixed model to each outcome
separately using all available data. A cell means model
will be used to estimate mean scores for each group by
time combination. An unstructured covariance type will
be used to model the covariance structure among re-
peated measures and all models will be estimated by
maximum likelihood. Group comparisons at post-baseline
time points will be performed using contrasts within the
proposed models. After inspection of the data, the appro-
priateness of stated methods will be revised, if necessary.
Because of the number of significance tests for secondary
outcomes, Hochberg’s modified Bonferroni procedure will
be used so that the overall type I error rate does not ex-
ceed 0.05 [33].
Discussion
CRC survivors represent a large and rapidly growing
group of people. It is critical that their serious and often
distressing needs following treatment completion are ap-
propriately managed. Unfortunately, there are few inter-
ventional studies that seek to improve psychosocial and
supportive care outcomes for cancer survivors and the
investigators identified no studies for patients with CRC,
following treatment completion.
This study will examine the impact of a nurse-led inter-
vention package for CRC survivors using important clin-
ical outcomes, such as distress, anxiety and depression, as
well as unmet needs and quality of life. SurvivorCare rec-
ognises treatment completion as a critical period. The
intervention is patient-centred, individually tailored and
nurse-led with active GP engagement. It screens for dis-
tress, provides evidence based information and coaching
in self-care and stress reduction. Patients are offered health
promotional strategies and, where appropriate, referred to
a broader multidisciplinary team. The effectiveness of the
intervention will be assessed in terms of important clinical
outcomes, specifically distress, anxiety and depression, un-
met needs and quality of life.
SurvivorCare has the potential to considerably reduce
individual suffering, but it is also likely to reduce the
cost of health provision to this group of patients, as fail-
ing to meet patients’ psychological and supportive care
needs results in longer hospital stays and higher medical
costs [34]. If the intervention is successful in achieving
the expected health benefits, it could be disseminated
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adapted to other cancer or chronic disease settings. By
encouraging consumer involvement in health care plan-
ning and promoting shared care between specialist treat-
ment centres and community services, the proposed
research program has the potential to transform health
care practices.
Trial status
Patient recruitment is open.
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